BR0315569A - Apresentação farmacêutica de liberação prolongada contendo alfuzosina - Google Patents
Apresentação farmacêutica de liberação prolongada contendo alfuzosinaInfo
- Publication number
- BR0315569A BR0315569A BR0315569-2A BR0315569A BR0315569A BR 0315569 A BR0315569 A BR 0315569A BR 0315569 A BR0315569 A BR 0315569A BR 0315569 A BR0315569 A BR 0315569A
- Authority
- BR
- Brazil
- Prior art keywords
- alfuzosine
- release
- functional layer
- prolonged release
- single functional
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Abstract
"APRESENTAçãO FARMACêUTICA DE LIBERAçãO PROLONGADA CONTENDO ALFUZOSINA". A presente invenção refere-se a composições farmacêuticas de alfuzosina ou sal farmaceuticamente aceitável, solvato, enantiómeros ou misturas desses, que liberam o ingrediente ativo durante um período de tempo prolongado. A composição farmacêutica pode ser uma apresentação farmacêutica oral de liberação prolongada que inclui uma camada funcional única e, opcionalmente, uma ou mais camadas não funcionais adjacentes à camada única funcional. A camada única funcional inclui alfuzosina ou seus sais farmaceuticamente aceitáveis, solvatos, enantiómeros ou misturas desses e um ou mais ingredientes retardadores de liberação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1056DE2002 | 2002-10-22 | ||
PCT/IB2003/004677 WO2004037228A1 (en) | 2002-10-22 | 2003-10-22 | Sustained release compositions containing alfuzosin |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0315569A true BR0315569A (pt) | 2005-08-30 |
Family
ID=34631110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0315569-2A BR0315569A (pt) | 2002-10-22 | 2003-10-22 | Apresentação farmacêutica de liberação prolongada contendo alfuzosina |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060147530A1 (pt) |
EP (1) | EP1556014A1 (pt) |
CN (1) | CN1720026A (pt) |
AU (1) | AU2003278407A1 (pt) |
BR (1) | BR0315569A (pt) |
EA (1) | EA200500672A1 (pt) |
MX (1) | MXPA05004338A (pt) |
WO (1) | WO2004037228A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060062846A1 (en) * | 2004-09-17 | 2006-03-23 | Cimex Pharma Ag | Alfuzosin tablets and synthesis |
EP1976488A4 (en) * | 2006-01-12 | 2010-02-10 | Wockhardt Ltd | ALFUZOSIN PROLONGED RELEASE PREPARATIONS |
US20070292505A1 (en) * | 2006-06-15 | 2007-12-20 | Abrika Pharmaceuticals, Inc. | Controlled release alfuzosin hydrochloride formulation |
US20080095844A1 (en) * | 2006-10-23 | 2008-04-24 | Rajhans Sujay Kamalakar | Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof |
WO2008073388A2 (en) * | 2006-12-11 | 2008-06-19 | Mutual Pharmaceutical Company, Inc. | Alfuzosin formulations, methods of making and methods of use |
US20100092556A1 (en) * | 2006-12-11 | 2010-04-15 | Kristin Arnold | Alfuzosin formulations, methods of making, and methods of use |
WO2008102235A1 (en) * | 2007-02-20 | 2008-08-28 | Aurobindo Pharma Limited | Controlled release formulations of alfuzosin |
US20100183717A1 (en) * | 2009-01-16 | 2010-07-22 | Kristin Arnold | Controlled-release formulations |
CN105287422A (zh) * | 2015-12-07 | 2016-02-03 | 黑龙江省智诚医药科技有限公司 | 一种盐酸阿夫唑嗪缓释片及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
US4680323A (en) * | 1983-12-01 | 1987-07-14 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
US4704285A (en) * | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
GB9311191D0 (en) * | 1993-05-29 | 1993-07-14 | Danbiosyst Uk | Controlled release drug formulation |
FR2717388B1 (fr) * | 1994-03-21 | 1996-11-22 | Synthelabo | Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine. |
US6096339A (en) * | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
SI0938318T1 (en) * | 1996-08-29 | 2001-12-31 | Sanofi Synthelabo | Tablet with controlled release of alfuzosine chlorydrate |
EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
FR2820319B3 (fr) * | 2001-02-08 | 2003-12-05 | Ellipse Pharmaceuticals | Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu |
-
2003
- 2003-10-22 MX MXPA05004338A patent/MXPA05004338A/es unknown
- 2003-10-22 WO PCT/IB2003/004677 patent/WO2004037228A1/en not_active Application Discontinuation
- 2003-10-22 BR BR0315569-2A patent/BR0315569A/pt not_active IP Right Cessation
- 2003-10-22 AU AU2003278407A patent/AU2003278407A1/en not_active Abandoned
- 2003-10-22 US US10/532,296 patent/US20060147530A1/en not_active Abandoned
- 2003-10-22 CN CNA2003801050883A patent/CN1720026A/zh active Pending
- 2003-10-22 EA EA200500672A patent/EA200500672A1/ru unknown
- 2003-10-22 EP EP03769713A patent/EP1556014A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MXPA05004338A (es) | 2005-06-22 |
EA200500672A1 (ru) | 2005-12-29 |
WO2004037228A1 (en) | 2004-05-06 |
US20060147530A1 (en) | 2006-07-06 |
AU2003278407A1 (en) | 2004-05-13 |
CN1720026A (zh) | 2006-01-11 |
EP1556014A1 (en) | 2005-07-27 |
WO2004037228A8 (en) | 2004-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070578L (no) | Oral doseringsform sikret mot misbruk inneholdende (1,2R)-3-(3-dimetylammino-l-etyl-2-metyl-propyl)-fenol | |
BR0001515A (pt) | Composições de espuma estáveis | |
IS7142A (is) | Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi | |
UY28026A1 (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos. | |
BR0113331A (pt) | Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica | |
BRPI0507735A (pt) | composição para administração oral de cloridrato de tamsulosin e formulação de gránulo de liberação controlada compreendendo a mesma | |
EA200400471A1 (ru) | Оральная дозированная форма пропиверина | |
CY1107966T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν μετφορμινη και γλιβενκλαμιδη για τη θεραπεια του σακχαρωδους διαβητη τυπου ii | |
NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
EE05400B1 (et) | Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks | |
HUP0300684A2 (hu) | Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NO20003196D0 (no) | Umiddelbart smeltende doseringsformulering | |
ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
ATE538797T1 (de) | Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon | |
ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
BRPI0418026A (pt) | derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças | |
RS54258B1 (en) | SRC / ABL INHIBITOR FORMULATIONS | |
RS54670B1 (en) | SOLID DOSAGE FORMULATION OF FENTANIL WITH IMPROVED BUCHAL ADSORPTION | |
BR0315569A (pt) | Apresentação farmacêutica de liberação prolongada contendo alfuzosina | |
BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
BR0114100A (pt) | Formulações de liberação controlada para administração oral | |
NO20034863L (no) | Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser | |
NO304113B1 (no) | Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament | |
BRPI0410044B8 (pt) | forma de dosagem contendo pantoprazol como ingrediente ativo | |
DE50109650D1 (de) | Topische behandlung bei der mastalgie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A , 6A , E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |